Related references
Note: Only part of the references are listed.Functionalization of Ruthenium(II) Terpyridine Complexes with Cyclic RGD Peptides To Target Integrin Receptors in Cancer Cells
Eva M. Hahn et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
Synthesis of Novel c(AmpRGD) Sunitinib Dual Conjugates as Molecular Tools Targeting the αvβ3 Integrin/VEGFR2 Couple and Impairing Tumor-Associated Angiogenesis
Andrea Sartori et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Nonconventional trans-Platinum Complexes Functionalized with RDG Peptides: Chemical and Cytototoxicity Studies
Maria Angeles Medrano et al.
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
Synthesis and biological evaluation of a Platinum(II)-c(RGDyK) conjugate for integrin-targeted photodynamic therapy
T. Chatzisideri et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
RGD-mediated delivery of small-molecule drugs
Sotirios Katsamakas et al.
FUTURE MEDICINAL CHEMISTRY (2017)
A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins
Tobias G. Kapp et al.
SCIENTIFIC REPORTS (2017)
Multifunctional αvβ6 Integrin-Specific Peptide-Pt(IV) Conjugates for Cancer Cell Targeting
Anne C. Conibear et al.
BIOCONJUGATE CHEMISTRY (2017)
New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry
Sergio A. Perez et al.
ACS CHEMICAL BIOLOGY (2017)
Advancement in integrin facilitated drug delivery
Daniela Arosio et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
αvβ3-or α5β1-Integrin-Selective Peptidomimetics for Surface Coating
Carlos Mas-Moruno et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2016)
Peptide-mediated vectorization of metal complexes: conjugation strategies and biomedical applications
Marta Soler et al.
DALTON TRANSACTIONS (2016)
Angiogenesis inhibitors as therapeutic agents in cancer: Challenges and future directions
Zhexuan Lin et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility
Anne Close
FUTURE MEDICINAL CHEMISTRY (2016)
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2015)
An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies
Albert Gandioso et al.
CHEMICAL COMMUNICATIONS (2015)
A Photoactivatable Platinum(IV) Anticancer Complex Conjugated to the RNA Ligand Guanidinoneomycin
Evyenia Shaili et al.
CHEMISTRY-A EUROPEAN JOURNAL (2015)
Integrin-targeted delivery into cancer cells of a Pt(IV) pro-drug through conjugation to RGD-containing peptides
Anna Massaguer et al.
DALTON TRANSACTIONS (2015)
Dual Antitumor and Antiangiogenic Activity of Organoplatinum(II) Complexes
Ana Zamora et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Novel C,N-Cyclometalated Benzimidazole Ruthenium(II) and Iridium(III) Complexes as Antitumor and Antiangiogenic Agents: A Structure-Activity Relationship Study
Jyoti Yellol et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics
Miriam Gongora-Benitez et al.
CHEMICAL REVIEWS (2014)
A rhodium(III) complex inhibits LPS-induced nitric oxide production and angiogenic activity in cellulo
Li-Juan Liu et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2014)
The Future of Peptide-based Drugs
David J. Craik et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Jonathan Welti et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Somatostatin Subtype-2 Receptor-Targeted Metal-Based Anticancer Complexes
Flavia Barragan et al.
BIOCONJUGATE CHEMISTRY (2012)
Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex
Anja Kastl et al.
CHEMICAL COMMUNICATIONS (2012)
A dual cytotoxic and anti-angiogenic water-soluble gold(III) complex induces endoplasmic reticulum damage in HeLa cells
Jing-Jing Zhang et al.
CHEMICAL COMMUNICATIONS (2012)
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis
Fabienne Danhier et al.
MOLECULAR PHARMACEUTICS (2012)
Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
J. B. Vermorken et al.
BRITISH JOURNAL OF CANCER (2011)
Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity
Patrycja Nowak-Sliwinska et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Iridium Complex with Antiangiogenic Properties
Alexander Wilbuer et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Carlos Mas-Moruno et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2010)
Integrins in cancer: biological implications and therapeutic opportunities
Jay S. Desgrosellier et al.
NATURE REVIEWS CANCER (2010)
Solid-phase synthesis and DNA binding studies of dichloroplatinum(II) conjugates of dicarba analogues of octreotide as new anticancer drugs
Flavia Barragan et al.
CHEMICAL COMMUNICATIONS (2009)
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway
Leticia Oliveira-Ferrer et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)
The CXC-Chemokine CXCL4 Interacts with Integrins Implicated in Angiogenesis
Sallouha Aidoudi et al.
PLOS ONE (2008)
αν-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin
T Taga et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)